NextCODE Buy Boosts WuXi’s Genomics Expertise
This article was originally published in PharmAsia News
Executive Summary
WuXi PharmaTech has acquired the genomic analysis company NextCODE Health for $65 million in cash. The Shanghai-based R&D technology firm plans to merge the NextCODE Health business into its own genome center, creating a new company to be known as WuXi NextCODE Genomics.